Sarepta Therapeutics, Inc. (SRPT) Financial Statements (2024 and earlier)

Company Profile

Business Address 215 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,879,7001,901,1002,008,4002,091,5001,946,6002,023,100
Cash and cash equivalents851,929871,668966,7771,038,624868,5651,233,877
Short-term investments1,008,7861,010,4291,022,5971,033,8601,059,454779,548
Other undisclosed cash, cash equivalents, and short-term investments18,98519,00319,02619,01618,5819,675
Receivables236,808223,836214,628201,509203,854178,194
Inventory, net of allowances, customer advances and progress billings226,876202,675203,968221,192208,095198,997
Inventory226,876202,675203,968221,192208,095198,997
Other current assets148,215179,769149,891130,744129,332140,331
Other undisclosed current assets(18,985)(19,003)(19,026)(19,016)(18,581)(9,675)
Total current assets:2,472,6142,488,3772,557,8612,625,9292,469,3002,530,947
Noncurrent Assets
Inventory, Noncurrent166,635164,144    
Operating lease, right-of-use asset134,72862,01664,95443,03446,99945,982
Property, plant and equipment188,874182,862180,037181,005183,292187,248
Intangible assets, net (including goodwill)   7,57813,05713,06213,328
Intangible assets, net (excluding goodwill)   7,57813,05713,06213,328
Other noncurrent assets163,039162,387317,936293,124284,200278,649
Total noncurrent assets:653,276571,409570,505530,220527,553525,207
TOTAL ASSETS:3,125,8903,059,7863,128,3663,156,1492,996,8533,056,154
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities436,673452,264514,871533,083473,189347,915
Interest and dividends payable2,9351,092
Employee-related liabilities42,68932,191
Accounts payable109,796106,71095,875118,46156,20754,007
Accrued liabilities326,877345,554418,996368,998383,699293,908
Deferred revenue44,98967,23989,24489,24489,24489,244
Other liabilities16,99217,38115,48926,21316,41617,803
Other undisclosed current liabilities    (45,624)(33,283) 
Total current liabilities:498,654536,884619,604602,916545,566454,962
Noncurrent Liabilities
Long-term debt and lease obligation1,235,5171,234,2841,544,2921,577,9991,140,2411,137,467
Long-term debt, excluding current maturities1,235,5171,234,2841,544,2921,542,7701,100,8731,098,847
Liabilities, other than long-term debt614,208538,969542,620507,494540,989563,239
Deferred revenue485,000485,000485,000507,494529,989552,239
Other liabilities 383842 11,00011,000
Operating lease, liability129,17053,93157,57835,22939,36838,620
Other undisclosed noncurrent liabilities36,10036,90036,90036,90043,60043,600
Total noncurrent liabilities:1,885,8251,810,1532,123,8122,122,3931,724,8301,744,306
Total liabilities:2,384,4792,347,0372,743,4162,725,3092,270,3962,199,268
Equity
Equity, attributable to parent741,411712,749384,950430,840726,457856,886
Common stock999999
Additional paid in capital5,193,3885,140,1504,296,8414,235,0284,272,1874,168,956
Accumulated other comprehensive loss(1,055)(419)(1,664)(3,205)(2,485)(306)
Accumulated deficit(4,450,931)(4,426,991)(3,910,236)(3,800,992)(3,543,254)(3,311,773)
Total equity:741,411712,749384,950430,840726,457856,886
TOTAL LIABILITIES AND EQUITY:3,125,8903,059,7863,128,3663,156,1492,996,8533,056,154

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues261,238253,500258,427230,269233,487210,830
Cost of revenue(34,124)(35,017)(22,910)(39,952)(37,795)(31,443)
Gross profit:227,114218,483235,517190,317195,692179,387
Operating expenses(360,633)(356,571)(342,350)(321,672)(406,824)(266,268)
Operating loss:(133,519)(138,088)(106,833)(131,355)(211,132)(86,881)
Nonoperating income (expense)118,934(374,622)5,527(125,063)(16,961)(17,265)
Investment income, nonoperating   (7,362)4,7802,409173
Other nonoperating income (expense)16,93412,707(33,671)3,634(3,342)(1,642)
Interest and debt expense(5,224)(387,329) (125,441)(16,028)(15,796)
Loss from continuing operations before equity method investments, income taxes:(19,809)(900,039)(101,306)(381,859)(244,121)(119,942)
Other undisclosed income from continuing operations before income taxes5,224387,329 125,44116,02815,796
Loss from continuing operations before income taxes:(14,585)(512,710)(101,306)(256,418)(228,093)(104,146)
Income tax expense(9,355)(4,045)(7,938)(1,320)(3,388)(879)
Loss from continuing operations:(23,940)(516,755)(109,244)(257,738)(231,481)(105,025)
Loss before gain (loss) on sale of properties:(257,738)(231,481)(105,025)
Net loss available to common stockholders, diluted:(23,940)(516,755)(109,244)(257,738)(231,481)(105,025)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(23,940)(516,755)(109,244)(257,738)(231,481)(105,025)
Other comprehensive income (loss)(636)1,2451,541(720)(2,179)(286)
Comprehensive loss, net of tax, attributable to parent:(24,576)(515,510)(107,703)(258,458)(233,660)(105,311)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: